Assessing the Burden of Opioid-Induced Constipation: In Pursuit of Fast Relief and Minimal Pharmacokinetic Drug–Drug Interactions

This monograph discusses the unmet needs in patients with opioid-induced constipation (OIC) based on the results of ...

SEPTEMBER 27, 2018

Can Opioids and Substance Abuse Disorder Coexist?

Controlling chronic noncancer pain in a patient who has a substance use disorder is a complex and challenging task. ...

AUGUST 15, 2017

Researchers: NPs in Primary Care Must Make Better Use of Opioid REMS

When it comes to prescribing and monitoring opioid use in patients suffering from chronic nonmalignant pain, family ...

JUNE 21, 2017

FDA Gives Tanezumab Fast Track Status for Chronic LBP

The FDA has granted fast track designation to tanezumab for treatment of osteoarthritis and chronic low ...

JUNE 15, 2017

FDA Approves Naldemedine for OIC in Adults With Chronic Noncancer Pain

The approval was based on reviewing data from three clinical trials showing the safety and efficacy of naldemedine ...

MARCH 24, 2017

Risk for Death Increases With Prescription Long-Acting Opioids Compared to Alternative Medications

Prescribing long-acting opioids for moderate to severe chronic noncancer pain is linked to higher rates of death ...

SEPTEMBER 15, 2016

FDA Approves Oral Formulation of Relistor for OIC in Adults

Methylnaltrexone subcutaneous injection (12 and 8 mg) was approved in 2008 for the treatment of OIC in adults ...

JULY 22, 2016

Naldemedine Improves Opioid-Induced Constipation in Patients With Chronic Noncancer Pain

Naldemedine treatment for 12 weeks significantly relieved opioid-induced constipation compared with placebo, as ...

APRIL 27, 2016